Nazila Habibizad - 01 Apr 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Executive Vice President, Operations
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Apr 2022
Net transactions value
-$19,391
Form type
4
Filing time
05 Apr 2022, 19:00:19 UTC
Previous filing
03 Aug 2022
Next filing
03 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +1,558 +5.4% 30,576 01 Apr 2022 Direct F1
transaction GBT Common Stock Tax liability $19,391 -540 -1.8% $35.91 30,036 01 Apr 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -1,375 -25% $0.000000 4,125 01 Apr 2022 Common Stock 1,375 Direct F1, F3
transaction GBT Restricted Stock Units Options Exercise $0 -183 -20% $0.000000 730 01 Apr 2022 Common Stock 183 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,558 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vest in eight semi-annual installments from October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F4 The shares of Common Stock underlying the RSUs vest in eight semi-annual installments from April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Executive Vice President, Operations